Lesinurad
As of the edition of 20 October 2026, Lesinurad is a small molecule: marketed, first approved in 2015 (US); acts on SLC22A12; US protection ends in 2032.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2015
- Kind
- Small molecule
- Brand name
- Zurampic
- First approved
- 22 December 2015 (US)
- Approvals on record
- 3 in 1 region
- Holder of the most recent approval
- Ironwood Pharmaceuticals
- Registered trials
- 21, 1 stopped early
- Disease areas
- Bones, joints and muscles; Inherited and neonatal; Nutrition and metabolism
US protection
US protection ends in 2032.
The last listed US drug-substance patent ends in 2032. The application that gives this date is held by Ironwood Pharmaceuticals.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Lesinurad.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SLC22A12 | Solute carrier family 22 member 12 | Q96S37 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 1 |
| Phase 1 | 11 | 11 | 0 | 0 |
| Phase 2 | 2 | 2 | 0 | 0 |
| Phase 3 | 7 | 7 | 0 | 0 |
| All trials | 21 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Ardea Biosciences | Originator and Lead sponsor of trials | 2009 to now |
| Ironwood Pharmaceuticals | Acquired holder | 2016 to now |